Acute liver failure: A systematic review and network meta-analysis of optimal type of stem cells in animal models

Table 1 League table of network meta-analysis estimations

Interventions	Outcomes
	ALT	AST	TNF-α	IL-6
ADMSCs vs AFMSCs	-564.66 (-2299.61, 1244.94)	333.03 (-3589.84, 4179.61)	-75.75 (-288.40, 135.39)	-83.75 (-240.12, 67.73)
ADMSCs vs BMSCs	-128.07 (-785.76, 520.77)	360.87 (-715.94, 1438.35)	-63.71 (-161.64, 37.04)	-72.42 (-155.32, 11.73)
ADMSCs vs LSCs	5933.08 (3909.44, 7997.17)1	9937.57 (6697.32, 13196.61)1	-55.42 (-215.17, 101.23)	64.61 (-91.38, 208.00)
ADMSCs vs MenSCs	-469.19 (-1740.82, 814.19)	45.27 (-2014.75, 2083.32)	-74.89 (-284.96, 141.77)	-86.05 (-240.23, 59.90)
ADMSCs vs Placebo	-667.52 (-1203.62, -120.99)1	-606.72 (-1506.56, 287.46)	-77.20 (-152.74, -1.88)1	-89.51 (-156.08, -28.79)1
ADMSCs vs UCMSCs	795.81 (46.64, 1560.45)1	1050.35 (-188.25, 2288.34)	37.30 (-72.01, 147.61)	-55.68 (-148.03, 34.58)
AFMSCs vs BMSCs	436.30 (-1349.95, 2166.93)	39.47 (-3802.42, 3952.36)	12.93 (-194.78, 220.48)	11.84 (-137.80, 164.77)
AFMSCs vs LSCs	6488.58 (3913.57, 9087.80)1	9604.11 (4643.34, 14441.26)1	18.65 (-224.35, 261.70)	148.58 (-49.07, 342.37)
AFMSCs vs MenSCs	82.07 (-1917.03, 2135.48)	-286.68 (-4498.58, 3913.27)	2.59 (-277.20, 281.02)	-2.79 (-200.21, 193.85)
AFMSCs vs Placebo	-114.65 (-1822.82, 1576.48)	-928.62 (-4714.44, 2892.00)	-1.11 (-201.89, 197.43)	-6.71 (-143.71, 133.84)
AFMSCs vs UCMSCs	1352.71 (-432.10, 3142.15)	724.02 (-3142.84, 4626.69)	114.19 (-99.91, 324.03)	28.52 (-122.68, 187.29)
BMSCs vs LSCs	6070.03 (4071.59, 8102.74)1	9576.33 (6336.42, 12727.97)1	7.85 (-144.90, 158.13)	136.42 (-15.99, 284.09)
BMSCs vs MenSCs	-341.05 (-1545.56, 858.89)	-322.93 (-2219.61, 1608.47)	-10.36 (-218.54, 200.58)	-13.77 (-163.34, 128.40)
BMSCs vs Placebo	-533.83 (-957.97, -124.80)1	-968.24 (-1654.55, -302.11)1	-13.45 (-79.67, 51.73)	-16.82 (-77.28, 33.66)
BMSCs vs UCMSCs	924.27 (248.03, 1604.46)1	693.88 (-410.09, 1801.40)	101.07 (-3.29, 205.02)	16.77 (-68.35, 99.68)
LSCs vs MenSCs	-6409.29 (-8678.76, -4138.55)1	-9871.16 (-13492.79, -6276.98)1	-19.14 (-258.98, 224.58)	-151.36 (-340.66, 43.49)
LSCs vs Placebo	-6600.26 (-8583.58, -4625.55)1	-10542.45 (-13603.53, -7407.19)1	-20.86 (-158.68, 119.97)	-154.33 (-290.19, -15.83)1
LSCs vs UCMSCs	-5138.64 (-7210.04, -3092.11)1	-8886.10 (-12104.64, -5633.36)1	93.80 (-66.86, 257.57)	-119.18 (-268.00, 37.35)
MenSCs vs Placebo	-204.31 (-1344.63, 944.68)	-639.98 (-2497.51, 1193.49)	-3.78 (-207.01, 193.79)	-3.14 (-138.85, 129.45)
MenSCs vs UCMSCs	1270.03 (-1.67, 2541.86)	1019.16 (-1023.95, 3022.83)	111.17 (-106.96, 327.48)	30.02 (-116.58, 179.83)
Placebo vs UCMSCs	1461.02 (918.17, 2019.69)1	1657.56 (793.12, 2525.40)1	114.68 (33.79, 197.01)1	33.87 (-27.82, 100.16)

¹Indicated statistical difference.

BMSCs: Bone marrow mesenchymal stem cells; LSCs: Liver stem cells; MenSCs: Menstrual blood-derived stem cells; AFMSCs: Amniotic fluid mesenchymal stem cells; ADMSCs: Adipose mesenchymal stem cells; UCMSCs: Umbilical cord mesenchymal stem cells; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TNF-α: Tumor necrosis factor-α; IL-6: Interleukin-6.